Transient receptor potential ion channel TRPM2 promotes AML proliferation and survival through modulation of mitochondrial function, ROS, and autophagy

Shu-jen Chen1, Lei Bao1, Kerry Keefer1, Santhanam Shamugapriya2, Longgui Chen1, John Lee1, JuFang Wang3, Xue-Qian Zhang3, Iwona Hirschler-Laszkiewicz1, Salim Merali4, Carmen Merali4, Yuka Imamura5, Sinisa Dovat1, Muniswamy Madesh2, Joseph Y. Cheung3, Hong-Gang Wang1, Barbara A. Miller1,5

Abstract
Transient receptor potential melastatin 2 (TRPM2) ion channel has an essential function in maintaining cell survival following oxidant injury. Here, we show that TRPM2 is highly expressed in acute myeloid leukemia (AML). The role of TRPM2 in AML was studied following depletion with CRISPR/Cas9 technology in U937 cells. In in vitro experiments and in xenografts, depletion of TRPM2 in AML inhibited leukemia proliferation, and doxorubicin sensitivity was increased. Mitochondrial function including oxygen consumption rate and ATP production was reduced, impairing cellular bioenergetics. Mitochondrial membrane potential and mitochondrial calcium uptake were significantly decreased in depleted cells. Mitochondrial reactive oxygen species (ROS) were significantly increased, and Nrf2 was decreased, reducing the antioxidant response. In TRPM2-depleted cells, ULK1, Atg7, and Atg5 protein levels were decreased, leading to autophagy inhibition. Consistently, ATF4 and CREB, two master transcription factors for autophagosome biogenesis, were reduced in TRPM2-depleted cells. In addition, Atg13 and FIP200, which are known to stabilize ULK1 protein, were decreased. Reconstitution with TRPM2 fully restored proliferation, viability, and autophagy; ATF4 and CREB fully restored proliferation and viability but only partially restored autophagy. TRPM2 expression reduced the elevated ROS found in depleted cells. These data show that TRPM2 has an important role in AML proliferation and survival through regulation of key transcription factors and target genes involved in mitochondrial function, bioenergetics, the antioxidant response, and autophagy. Targeting TRPM2 may represent a novel therapeutic approach to inhibit myeloid leukemia growth and enhance susceptibility to chemotherapeutic agents through multiple pathways.

Introduction
Increased reactive oxygen species (ROS) are found in acute myeloid leukemia (AML). Mitochondria are a major source of ROS, which injure tissues through protein oxidation, lipid peroxidation, and DNA oxidation and mutagenesis. In malignant cells, a moderate rise in ROS may promote proliferation and metastasis by aberrantly affecting proliferative or survival pathways, whereas an excessive increase results in cell death. Malignant cells produce more ROS than normal cells, and a number of chemotherapy agents including doxorubicin mediate cell death by increasing ROS above a cytotoxic threshold.
In myeloid leukemia, use of pro-oxidants or inhibition of intracellular antioxidants to increase ROS above the cytotoxic threshold has been proposed as a novel approach to optimize anti-cancer drugs. Myeloid leukemia stem cell have increased sensitivity to ROS, which could be utilized in their eradication.

TRP channels are members of a superfamily of cation-permeable ion channels involved in fundamental cell functions. Melastatin subfamily (TRPM) members have important roles in cell proliferation and survival. TRPM2, the second member of this subfamily to be cloned, is expressed in many cell types, including hematopoietic and mediates cation influx. Oxidative stress (H2O2) and TNFs are extracellular signals which regulate TRPM2 through production of ADP-ribose (ADPR), which binds to the TRPM2 C-terminal domain, activating the channel. TRPM2 is also positively regulated by the intracellular Ca²⁺ concentration.

The ion channel TRPM2 is highly expressed in a number of cancers. While early studies supported the concept that TRPM2 activation induced cell death by sustained increase in intracellular calcium or enhanced cytokine production, recent investigations concluded that physiological Ca²⁺ entry via TRPM2 channels is protective rather than deleterious, consistent with high expression in cancer. TRPM2 channels protect hearts of mice from ischemia/reperfusion (I/R) injury. A TRPM2 mutant (P1018L) was found in Guamanian amyotrophic lateral sclerosis and Parkinsonism dementia patients. Unlike wild-type TRPM2 which does not inactivate, the P1018L mutant inactivates after channel opening, limiting Ca²⁺ entry and suggesting TRPM2 is necessary for normal neuronal function. TRPM2 inhibition reduced neuroblastoma growth and enhanced chemotherapeutic responsiveness through decreased mitochondrial function and increased ROS.

Autophagy is required for maintenance of murine hematopoietic stem cells, and reduction of ULK1 activity, a critical kinase, decreased hematopoietic stem cell survival. Impaired autophagy may initially support pre-leukemia development and overt leukemic transformation through stabilization of oncoproteins, but once leukemia is established, autophagy promotes tumor growth, cell survival, and chemotherapy resistance. Inhibition of autophagy is an effective approach to improve chemotherapeutic response in myeloid leukemia. In neuroblastoma and gastric cancer, inhibition of TRPM2 reduced autophagy, although mechanisms were not completely defined.

The role of TRPM2 in AML proliferation and chemotherapy sensitivity was examined here using myeloid leukemia cells in which TRPM2 was depleted. Major findings are as follows: (1) TRPM2 is highly expressed in AML and depletion of TRPM2 inhibits leukemia proliferation and survival in vitro and in xenografts; (2) mitochondrial function and bioenergetics are reduced and mitochondrial ROS levels elevated in TRPM2-depleted leukemia cells; (3) multiple transcription factors including CREB, ATF4, and Nrf2 are reduced in TRPM2 depletion, which contributes to increased ROS; and (4) autophagy is impaired through modulation of transcription factors CREB and ATF4, which are master transcription factors for autophagosome biogenesis, resulting in decreased ULK1, Atg7, and Atg5 and autophagocytic flux. These findings demonstrate that inhibition of TRPM2 reduces leukemia growth and increases cytotoxicity in myeloid leukemia through mitochondrial dysfunction, increased mitochondrial ROS production, reduced antioxidant response and bioenergetics, and significantly impaired autophagy.

**Results**

**TRPM2 is highly expressed in AML**

High levels of TRPM2 mRNA were found in human AML cell lines compared with normal CD33⁺ or CD34⁺ precursors isolated from human bone marrow. TRPM2 mRNA measured in bone marrow samples from untreated AML patients was significantly greater than that in normal human CD33⁺ or CD34⁺ samples but less than in AML cell lines. TRPM2 mRNA quantitated in hematopoietic cells was significantly greater than that in neuroblastoma SH-SY5Y cells.

To confirm high TRPM2 expression in AML, TRPM2 expression in AML patients (n = 1889) and normal human bone marrow hematopoietic progenitor cells was examined using the Bloodspot data set (Fig. 1b). Expression of TRPM2 in AML samples from patients with normal karyotypes and all major AML mutational subgroups including aberrant complex karyotypes was significantly greater than that measured in normal hematopoietic stem cells (HSC) or common myeloid progenitors (CMP) (Fig. 1b). This demonstrated that TRPM2 expression was higher in AML than in normal hematopoietic cells at similar stages of differentiation.

TRPM2 protein expression was examined with western blotting of CD34⁺ cells and AML cell lines (Fig. 1c). TRPM2 protein expression was increased in eight of nine myeloid cell lines compared with normal precursors, similar to mRNA measured with RT-PCR.

**Generation and characterization of TRPM2-depleted U937 cells**

To examine the function of TRPM2 in myeloid leukemia, TRPM2 was depleted from U937 leukemia cells with CRISPR/Cas9 technology. TRPM2 genomic DNA sequence encoding the first 40 amino acids was deleted and the remaining sequence was frameshifted. Single
cell clones from TRPM2 knockout and control cells were generated and expanded. Deletion of TRPM2 in these clones was confirmed by RT-PCR (Fig. 2a) and western blotting (Fig. 2b). Three TRPM2-depleted and three scrambled control clones were randomly selected for functional experiments. Parental U937 cells (Wt), U937 cells in which TRPM2 was depleted (KO), or control cells targeted with scrambled gRNA (Scr) were subjected to
patch-clamp. Intracellular application of ADPR (300 µM) elicited large inward and outward cation currents in Wt and scrambled cells, but not KO cells (Fig. 2c). ADPR-activated currents displayed the characteristic TRPM2 linear I–V relationship with reversal potential close to 0 mV. Omission of ADPR in pipette solutions resulted in much smaller currents in Wt or Scr cells similar to those measured in KO cells in which ADPR was included. These characteristics indicate that: (1) the ADPR-activated current in U937 cells is mediated by TRPM2; and (2) TRPM2 channel activity is absent in KO cells.

**Cell proliferation is reduced and doxorubicin sensitivity increased in TRPM2-depleted myeloid cells**

Cell proliferation quantified by trypan blue exclusion (Fig. 3a) or XTT analysis (Fig. 3b) was significantly reduced in TRPM2-depleted U937 cells compared with scrambled control clones. Comparing Scr and KO cells, there were significant group (p < 0.0001), time (p < 0.0001), and group × time interaction (p < 0.0001) effects, demonstrating that differences in proliferation were amplified with time. Doxorubicin treatment resulted in significantly reduced number of live cells (Fig. 3c, p < 0.0001) and increased number of dead cells (Fig. 3d, p < 0.0001) at 48 or 72 h in TRPM2-depleted cells compared with scrambled controls, measured with trypan blue exclusion. Cell viability was significantly lower in KO cells after treatment (Fig. 3e, p < 0.0001).

To eliminate the possibility of off-target effects during CRISPR/Cas9 treatment, TRPM2-depleted U937 cells were transfected with empty vector or wild type TRPM2. Expression of TRPM2 but not empty vector restored cell proliferation (Fig. 3f). Cell viability, and number of live and dead cells after doxorubicin in reconstituted TRPM2-depleted cells was restored to that in scrambled controls (Fig. 3g–i). This demonstrates the absence of significant off-target effects and the critical role of TRPM2 in AML proliferation and doxorubicin sensitivity.

To examine the importance of TRPM2 in leukemia growth in vivo, NSG female mice were injected intravenously with 8 × 10^3 TRPM2-depleted, or scrambled control U937 cells, infected with the pCDH-EF1-Luc2-P2A-tdTomato vector. These cells showed stable and equivalent luciferase expression prior to injection. Leukemia growth was measured for 16-17 days. Mice injected with TRPM2-depleted cells demonstrated significantly reduced leukemia compared with scrambled controls in three experiments (Fig. 3j, k; Supplemental Information Fig. 2).

**Mitochondrial function is significantly reduced in TRPM2-depleted AML cells**

Because ROS were increased in neuroblastoma cells depleted of TRPM2, mitochondrial ROS were...
quantitated in TRPM2-depleted myeloid leukemia cells using MitoSOX Red and confocal microscopy. Untreated TRPM2-depleted U937 cells showed significantly greater mitochondrial ROS than scrambled control cells. ROS dramatically increased in TRPM2-depleted cells following doxorubicin treatment (Fig. 4a).

To further examine mitochondrial function in TRPM2-depleted myeloid leukemia cells, oxygen consumption...
rates (OCR) and ATP production were quantitated. Basal and maximal OCR were significantly lower in TRPM2-depleted cells compared with scrambled control cells (Fig. 4b). Similarly, following doxorubicin treatment, basal and maximal OCRs were significantly lower in TRPM2-depleted cells compared with controls (Fig. 4c). ATP levels were significantly lower in TRPM2-depleted cells compared with scrambled controls after treatment with doxorubicin (Fig. 4d), and were fully restored after TRPM2 reconstitution (Fig. 4e). In addition, ROS levels were significantly reduced to the level in controls (Fig. 4f). This demonstrates the critical role of TRPM2 in bioenergetics and in regulation of mitochondrial ROS in AML.

Mitochondrial function was further evaluated by measurement of mitochondrial membrane potential (ΔΨm) and mitochondrial calcium uptake. ΔΨm was lower in KO cells compared with parental control cells measured with JC-10 (Fig. 5a, b). Results were confirmed with TMRE (tetramethylrhodamine, ethyl ester; data not shown). The rate of mitochondrial Ca2+ uptake after a single extramitochondrial 3 μM Ca2+ pulse was significantly lower in TRPM2 KO cells compared with wild type, both before and after doxorubicin treatment (Fig. 5c). After exposure to six extramitochondrial Ca2+ pulses, wild type myeloid cells took up significantly more Ca2+ than TRPM2-depleted, as indicated by clearance of more cytoplasmic Ca2+ pulses (Fig. 5d, e).

To determine whether TRPM2 depletion may affect mitochondrial function and ROS levels through modulation of mitochondrial electron complex proteins, mitochondrial protein expression was assessed with label-free proteomics analysis. This demonstrated reduction in proteins involved in mitochondrial electron transport Complexes I, II, and IV in TRPM2-depleted U937 cells compared with scrambled controls (Fig. 5f). After doxorubicin treatment, the differential expression became greater in Complexes I and IV, and also involved proteins in Complex V (Fig. 5g). Proteins with greatest changes are highlighted in Fig. 5f. Changes in mitochondrial proteins were confirmed including increase in cytochrome c oxidase subunit 6B1 (COX6B1) and decrease in NADH:ubiquinone oxidoreductase (NDUFA13) in KO cells, and after doxorubicin an increase in mitochondrial NADH dehydrogenase subunit (MT-ND2) and decrease in cytochrome c oxidase subunit II (MT-CO2) in the KO (Fig. 5h). Together, results demonstrate significant impairment of mitochondrial function, reduced cellular bioenergetics, and increased ROS, contributing to reduced cell proliferation and survival, and increased doxorubicin sensitivity.

Transcription factors HIF-1α, Nrf2, CREB, and ATF4 are reduced in TRPM2-depleted myeloid cells

To further examine mechanisms of reduced cell survival and mitochondrial function in TRPM2-depleted leukemia cells, expression of transcription factors involved in regulation of mitochondrial proteins and antioxidants was examined with Western blotting. Expression of HIF-1α and HIF-2α, which are regulated by calcium dependent pathways and involved in modulation of mitochondrial proteins including members of the ETC, were decreased in TRPM2-depleted U937 leukemia cells, as was the downstream transcription factor FOXO3a (Fig. 6a). Nrf2, a transcription factor which regulates expression of many cellular antioxidant genes, was also significantly decreased in TRPM2-depleted cells (Fig. 6a). IQGAP1, which stabilizes Nrf2 through a calcium dependent process, was decreased in TRPM2 depletion (Fig. 6a) and may contribute to the decrease in Nrf2 on a posttranslational level. Through mitochondrial and ETC dysfunction, the decrease in HIF-1α may contribute to increased ROS production and the decrease in FOXO3a and Nrf2 to reduced antioxidant capacity. Phosphorylated and total CREB, which regulate expression of proteins involved in mitochondrial function, and activating transcription
factor 4 (ATF4), which has an important role in autophagy, were significantly reduced in TRPM2-depleted cells (Fig. 6a, b). To determine if these key transcription factors are reduced on a transcriptional basis, HIF-1α, HIF-2α, and CREB mRNA were quantitated. RT-PCR determined that HIF-1α, HIF-2α, and CREB are at least partially reduced on a transcriptional basis (Fig. 6c).

**Autophagy is significantly impaired by TRPM2 depletion**

Autophagy is an important pro-survival mechanism which eliminates damaged mitochondria and controls levels of ROS. Because mitochondria are dysfunctional in TRPM2-depleted leukemia cells and ROS levels are increased, the effect of TRPM2 depletion on autophagy was examined. Low levels of ULK1, Atg7, and Atg5 were found in the KO (Fig. 6b). Conversion of LC3B-I to II was reduced and levels of Tom20 were increased in KO cells, confirming impaired autophagy. Another autophagy substrate, p62, may increase if autophagy is impaired; its decrease in TRPM2 KO cells may be secondary to downregulation of Nrf2, a known transcription factor regulating p62 expression.

ULK1, Atg7, and Atg5 are transcriptional targets of CREB and ATF4, suggesting autophagy may be reduced on a transcriptional basis. RT-PCR confirmed a significant decrease in CREB, ULK1, and Atg7 mRNAs, as well as...
HIF-1α mRNAs, in TRPM2-depleted cells (Fig. 6c). Atg13, FIP200, and Atg101, which play a role in ULK1 protein stability, were examined. Atg13 and FIP200 but not Atg101 were significantly lower in TRPM2-depleted cells (Fig. 6b), suggesting that the decrease in ULK1 may be secondary to both transcriptional and posttranslational mechanisms. To confirm reduced autophagic flux in TRPM2-depleted cells, the lysosomal turnover of LC3B-II was examined in the presence or absence of bafilomycin A1, a lysosomal inhibitor widely used to block autophagic degradation. While treatment with bafilomycin A1 increased LC3B-II levels in both control and KO cells, autophagic flux, as measured by the difference of LC3B-II levels between the bafilomycin A1 treated and untreated cells, was significantly reduced in TRPM2 KO cells (Fig. 6d).

Reconstitution of TRPM2 but not empty vector restored expression of CREB, ATF4, autophagy proteins ULK1, Atg7, and Atg5, and conversion of LC3B-I to II (Fig. 6e). These experiments demonstrate the key role of TRPM2 in regulation of autophagy, through both transcriptional and post translational pathways.

**AML-193 leukemia cells also demonstrated decreased proliferation and viability and reduced autophagy protein expression in TRPM2 knockdown**

To confirm findings in another AML cell line, AML-193 cells were stably transfected with shRNAs targeted to TRPM2 or scrambled control shRNAs. Reduction of TRPM2 was confirmed by western blotting (Fig. 7f). Cell proliferation (Fig. 7a, two experiments) and viability at 48 h after doxorubicin (Fig. 7b) measured by XTT were significantly lower in cells in which TRPM2 expression was reduced. The number of live cells at 24 and 48 h after doxorubicin, measured by trypan blue exclusion, was significantly reduced in TRPM2-depleted cells (Fig. 7c) and the number of dead cells was significantly increased (Fig. 7d). Percent cell viability was significantly reduced in TRPM2-depleted cells (Fig. 7e). Decreased expression of ULK1, Atg7, Atg5, and CREB was also demonstrated when TRPM2 was reduced in these cells (Fig. 7f).

**Reconstitution of ATF4 or CREB in TRPM2-depleted cells restores proliferation, survival and autophagy**

To determine their role in modulation of autophagy by TRPM2, TRPM2-depleted U937 cells were transfected with ATF4 or CREB. The ability of ATF4 or CREB to restore proliferation and viability of TRPM2-depleted cells treated with doxorubicin to that of scrambled control cells was examined. Data were analyzed by two-way ANOVA. Comparing all four groups in proliferation studies (Scr-V, KO-V, KO-ATF4, KO-CREB), there were significant differences in group ($p < 0.0001$), time ($p < 0.0001$), and group × time interaction effects ($p < 0.0001$), indicating that difference in proliferation between groups is amplified with time (Fig. 8a). Applying the Bonferroni correction to subgroup analyses (Scr-V vs KO-V, KO-V vs KO-ATF4, and KO-V vs KO-CREB) so that $p < 0.0167$ is statistically significant, group ($p < 0.0001$), time ($p < 0.0001$) and group × time interaction effects ($p < 0.0122$) were significantly different for all three subgroup comparisons. When cells were treated with doxorubicin, there were significant group and time effects in cell viability (Fig. 8 b), live cell number (Fig. 8c), and dead cell number (Fig. 8d). In three subgroup analyses, comparing Scr-V vs KO-V, KO-V vs KO-ATF4, and KO-V vs KO-CREB, significant differences in group ($p < 0.0004$) and time ($p < 0.0001$) (Fig. 8b, c) were achieved. The number of dead cells after doxorubicin was significantly different in all
three subgroup comparisons for group ($p < 0.0001$), time ($p < 0.0001$), and group × time interaction effects ($p < 0.009$, Fig. 8d). These data demonstrate the role of ATF4 and CREB in preserving proliferation and cell viability in TRPM2 expressing cells. Expression of ULK1, Atg7, and Atg5 were examined with western blotting.
ATF4 significantly restored autophagy proteins ULK1, Atg7, Atg5, and conversion of LC3B-I to II to levels above those in TRPM2-depleted cells, but only Atg7 to levels measured in Scr control (Fig. 8e). ULK1 was also significantly restored by CREB; Atg7 and Atg5 tended to be partially restored, but results did not reach statistical significance (Fig. 8e). Reconstitution of CREB also restored ATF4 expression and ATF4 restored CREB.

**Discussion**

TRPM2 is highly expressed in human AML cells. When TRPM2 is depleted, AML cell proliferation and survival after anthracycline chemotherapy are reduced. Mitochondrial function and cellular bioenergetics are significantly impaired and ROS are increased due to electron transport chain (ETC) dysfunction and decreased Nrf2. In addition, TRPM2 depletion dramatically reduced expression of key autophagy associated proteins including ULK1, Atg7, and Atg5 through mechanisms involving CREB and ATF4. This work demonstrates the significant roles of TRPM2 in cell viability, mitochondrial function, ROS regulation, and autophagy in AML.

The first major finding of this report is that TRPM2 expression is increased in leukemia cells of patients with AML, suggesting TRPM2 is pro-survival. Indeed, TRPM2 depletion significantly inhibited human leukemia proliferation and increased leukemia sensitivity to doxorubicin (Fig. 3). This is consistent with reports in neuroblastoma, T-cell ALL, and gastric cancer in which TRPM2 depletion reduced malignant cell survival. It differs from a report examining AML generated on a Trpmt2-/- genetic background in murine hematopoietic cells induced by retroviral introduction of MLL-AF9 or BCR-ABL-GFP and NUP98-HOXA9-YFP. Loss of TRPM2 in that model had no major effect on leukemogenesis or potentiation of cytotoxic therapy. That models differs from the one reported here in that the leukemia was induced in murine cells with retroviral vectors encoding aggressive genetic subtypes, and those mice had time to develop compensatory pathways.

The second major finding here is that mitochondrial function is significantly decreased and ROS increased in TRPM2-depleted human myeloid leukemia cells, particularly after doxorubicin exposure. A proposed schema of pathways through which TRPM2 sustains mitochondrial function and cell survival is shown on Fig. 8f. Mitochondrial proteins including those involved in ETC complexes, oxygen consumption, ATP production, and mitochondrial calcium uptake are significantly reduced in TRPM2 depletion and contribute to decreased leukemia survival and increased susceptibility to doxorubicin. Decrease in transcription factors including HIF-1/2α, FOXO3a, and CREB in TRPM2-depleted leukemia cells, a third finding of this report, contributes to ETC dysfunction through reduced ETC protein expression, increasing mitochondrial ROS and reducing ATP. In addition, a steady, low level of Ca2+ uptake by mitochondria is essential for maintenance of cellular bioenergetics and is decreased with TRPM2 depletion.

Nrf2 is a transcription factor which regulates expression of over 200 genes including many antioxidants. Reduction in Nrf2 and accumulation of ROS restricts self-renewal of hematopoietic stem cells. While Nrf2 protects non-malignant cells from oxidative stress and transformation by activation of antioxidant enzymes, it also protects malignant cells from oxidative stress and cytotoxic chemotherapy. A major finding of this report is that Nrf2 is significantly reduced in TRPM2 depletion in leukemia, contributing to increased ROS and chemotherapy sensitivity. Calcium impacts Nrf2 signaling through IQGAP1, a GTPase activating protein which stabilizes Nrf2. Increased intracellular calcium enhances translocation of Nrf2 and the Nrf2/IQGAP1 complex into the nucleus, increasing Nrf2 mediated target gene transcription. In contrast, silencing of IQGAP1 decreases Nrf2 expression and expression of Nrf2 target genes. In TRPM2-depleted leukemia cells, expression of IQGAP1 is decreased, contributing to reduced Nrf2 stability. These data show that the ROS increase in TRPM2-depleted cells results both from increased production by compromised...
ETC and an impaired antioxidant response. Of note, increased intracellular ROS may also contribute to mitochondrial dysfunction through oxidation of mitochondrial proteins.

The fourth major finding is that through modulation of transcription factors CREB and ATF4, TRPM2 regulates expression of ULK1, Atg7 and Atg5, significantly impacting autophagy. ROS induce autophagy, which eliminates damaged mitochondria and controls cellular ROS levels. Autophagy is a pro-survival mechanism in hematopoietic disease and promotes resistance to chemotherapy whereas blockade of autophagy increases chemotherapy sensitivity in AML. Autophagy and ATF4 play a key role in FLT3-ITD mutation mediated
leukemia proliferation and survival. Autophagy inhibition or downregulation of ATF4 overcame FLT3 inhibitor resistance and inhibited cell proliferation. In TRPM2 depletion, autophagy is suppressed, contributing to accumulation of dysfunctional mitochondria, increased ROS and anthracycline sensitivity, and cell death. These data suggest that TRPM2 inhibition may also have a therapeutic role in AML through inhibition of autophagy.

Autophagy is regulated by the ULK1 complex, which plays a key role in autophagosome formation and ULK1 mRNA levels positively correlate with reduced relapse-free survival and therapeutic resistance in breast cancer and nasopharyngeal carcinoma. In TRPM2-depleted cells, ULK1 is reduced by transcriptional and post-translational mechanisms. ULK1 transcription may be affected by both decreased ATF4 and CREB. ULK1 is a target of ATF4, a master regulator of transcription of genes involved in adaptation to stress, which is suppressed in TRPM2 depletion. Nrf2 is a positive regulator of ATF4, and reduced Nrf2 may contribute to decreased ATF4. Atg5 may also be modulated indirectly through NRF2-dependent transcription of the autophagy genes including CREB binding protein, or posttranslational mechanisms. TRPM2 also modulates ULK1 through post-translational mechanisms, and ULK1 is part of a multimeric protein complex composed of Atg13, RB1/FIP200, and Atg101, which are phosphorylated by ULK1 and Nrf2, ATF4, and CREB, and the autophagy regulators ULK1, Atg7, and Atg5. Together, these data strongly suggest that TRPM2 regulates these transcription factors are involved in ULK1 regulation and FOXO3a and CREB phosphorylation in TRPM2-depleted leukemia cells. Results summarizing two (TRPM2, ULK1), three (Atg7) or four (HIF-1/2α, CREB) experiments are shown (mean ± s.e.m., n = 8-16). *p < 0.05, one-way ANOVA. U937 cell were incubated with or without baflomycin A1, and conversion of LC3B-I to II was examined with western blotting. Four experiments were performed. One blot is shown here and the others in Supplemental Information Fig. 6. Densitometry measurements were obtained. Relative autophagic flux was calculated as: (O.D. LC3B-II + Baflomycin/OD. Actin) - (O.D. LC3B-II-Baflomycin/OD. Actin) for each band. Means ± s.e.m. for the four experiments for each cell line are shown below the figure (n = 8). *p < 0.05, unpaired, two-tailed t-test.

Western blotting was performed to measure TRPM2, CREB, Atg7, ULK1, Atg5, and LC3B-I and II expression in four experiments after TRPM2-L reconstitution. One blot is shown here and the others in Supplemental Information Fig. 7. Densitometry measurements were normalized to each bands untreated scrambled control, and mean densitometry measurements ± s.e.m. for experiments with each protein are shown on the right. "p < 0.04 (n = 4) one-way ANOVA."

Materials and methods

TRPM2 expression in AML patient samples, leukemia cell lines, and hematopoietic precursors

AML patient samples were obtained from the Institute of Personalized Medicine (IPM) at the Pennsylvania State University College of Medicine under protocols approved by the Institutional Review Board. Consent was obtained at sample collection by the IPM tumor bank and was not required for this study by the Institutional Review Board.
because samples were de-identified. Human myeloid leukemia cell lines and neuroblastoma cell line SH-SY5Y were purchased from American Type Culture Collection (ATCC, Manassas, VA, USA). Human bone marrow CD33+ and CD34+ cells were purchased from STEMCELL Technologies (Vancouver, BC, Canada).
Bloodspot BloodPool Data Set, AML samples with normal cells, was utilized to examine TRPM2 expression in HSCs (Lin^−/CD34^+/CD38^−/CD90^-/CD45RA^-), CMPs from normal human bone marrow (CMP), and AML samples with different cytogenetic mutations^59. Western blotting was performed as described.
Depletion of TRPM2

U937 cells were depleted of endogenous TRPM2 with CRISPR (Clustered regularly-interspaced short palindromic repeats) technology as described\(^3\). Multiple single cell clones were generated and expanded. TRPM2 depletion was confirmed with RT-PCR and western blotting. Three clones with TRPM2 depletion were chosen at random for experiments. In reconstitution experiments, U937 cells in which TRPM2 was depleted were transfected with wild type TRPM2 subcloned into pcDNA3.1/V5-His TOPO plasmid, ATF4 or CREB subcloned into pCMV6-Entry vector, or empty vector using the Neon Transfection System (Invitrogen, USA). Stably transfected were generated and maintained in 200 µg/ml G418 (Gemini Bio-Products, West Sacramento, CA, USA). Plates were treated with doxorubicin (0.1 to 0.5 µg/ml) when cells were 70–80% confluent. For xenograft experiments, TRPM2-depleted and scrambled U937 cell lines were generated which express luciferase and tdTomato using the pCDH-EF1-Luc2-P2A-tdTomato lentiviral plasmid (Addgene, Cambridge, MA, USA). TRPM2 current were measured in TRPM2-depleted or scrambled control cells with whole cell patch-clamp as described. Cell proliferation and viability were assessed using XTT (2,3-Bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide) proliferation assay (Trevigen Inc., Gaithersburg, MD, USA) or by cell counting with trypan blue exclusion. In some experiments, TRPM2 was reduced in AML-193 cells by infection with lentivirus expressing shRNA targeted to TRPM2 (Origene, Rockville, MD, USA). Cells infected with lentivirus were enhanced by selection with cell sorting for GFP, expressed by the lentivirus vector, and infected with lentivirus were enhanced by selection with cell sorting for GFP, expressed by the lentivirus vector, and are a pooled population. U937 and AML-193 cells were utilized here because they are frequently used in experiments on myeloid leukemia, they showed detectable levels of TRPM2 by Western blotting, and knockout clones and/or knockdown cell lines were successfully generated.

RT-PCR of endogenous TRPM2, ULK1, Atg7, and CREB expression in leukemia

TRPM2 mRNA was quantitated in leukemia samples and cell lines, and normal CD33+/CD34+ precursors as described. Primers/probes for HIF-1α (Assay ID Hs00153153-m1), HIF-2α (Assay ID Hs01026149-m1), ULK1 (Assay ID Hs0177504-m1), Atg7 (Assay ID Hs00893766-m1), CREB (Assay ID Hs00231713) and TATA Binding Protein Control (ID Hs00427620) were from Applied Biosystems (Waltham, MA, USA). Blots were probed with anti-TRPM2-C (1:300; Bethyl Laboratories, Montgomery, TX, USA); with antibodies to ATF4 (1:400), Atg7 (1:2000), Atg13 (1:500), Atg101 (1:500), pCREB1 and CREB1 (1:250), FIP200 (1:300), forkhead box transcription factor 3a (FOXO3a; 1:400), HIF-1α (1:250), Nrf2 (1:400), and ULK1 (1:1000) from Cell Signaling Technology (Boston, MA, USA); Atg5 (1:1000) from Medical Biological Lab (Japan); COX6B1 (1:500), MT-CO2 (1:500), MT-ND2 (1:500), and NDUFA13 (1:300) from LSBio (Seattle, WA, USA); HIF-2α (1:500) and LC3B (1:2000) from Novus (Littleton, CO, USA); IQGAP1 (1:5000) from Abcam (Cambridge, MA, USA); p62 (1:5000) from American Research Products (Waltham, MA, USA); Tom20 (1:5000) from Santa Cruz Biotech (Dallas, TX, USA); and actin (1:5000) from Sigma (St. Louis, MO, USA). Blots were incubated with horseradish peroxidase (HRP)-conjugated antibodies (1:2000). Enhanced chemiluminescence was used for detection of signal and intensity of bands quantitated with densitometry. In all cases, gels were transferred to filter paper, and the filters were cut into small molecular weight spans prior to probing. The entire portion of the western blot which was probed which each antibody is shown, except for TRPM2, which had a significant amount of empty space above the TRPM2 band. Figures were prepared with Adobe Photoshop Elements 7.

Measurements of mitochondrial function

Mitochondrial membrane potential (ΔΨm) was measured with JC-10 Mitochondrial Membrane Potential Assay Kit or the TMRE Kit (Abcam), using flow cytometry and manufacturer’s instructions. Mitochondrial Ca\(^{2+}\) uptake, oxygen consumption rate (OCR), ATP levels, and mitochondrial ROS were measured as described\(^4\).
Proteomic analysis

For label-free proteomics studies, extracted proteins were digested with trypsin. Mass spec analysis was performed using QE mass spectrometer as described previously.

Statistical analysis

Results are expressed as mean ± s.e.m.. The sample size for each experimental group and a statement of the number of experiments performed in each figure subsection is provided in figure legends. For analysis of TRPM2 current as a function of group and voltage, two-way analysis of variance (ANOVA) was used. For analysis of protein expression levels, O2 consumption, XTT, trypan blue exclusion, ATP levels, and ROS levels, two-way ANOVA, one-way ANOVA or t-tests were used as indicated. In analyses, p ≤ 0.05 was considered statistically significant or as specified when Bonferroni correction applied to two-way ANOVA analysis.

Acknowledgements

This research was supported by NIH grant RO1GM117014, The Four Diamonds Fund of the Pennsylvania State University, and The Hyundai Hope on Wheels Scholar Award.

Author details

1 Department of Pediatrics, The Pennsylvania State University College of Medicine, P.O. Box 850, Hershey, PA 17033, USA. 2 Department of Molecular Genetics and Medical Biochemistry, Temple University, Philadelphia, PA 19140, USA. 3 The Center of Translational Medicine, Temple University School of Medicine, Philadelphia, PA, USA. 4 School of Pharmacy, Temple University, Philadelphia, PA 19140, USA. 5 Department of Biochemistry and Molecular Biology, The Pennsylvania State University College of Medicine, P.O. Box 850, Hershey, PA 17033, USA. 6 Department of Pharmacology, The Pennsylvania State University College of Medicine, P.O. Box 850, Hershey, PA 17033, USA. 7 The Institute for Personalized Medicine, The Pennsylvania State University College of Medicine, P.O. Box 850, Hershey, PA 17033, USA. 8 Department of Medicine, Temple University, Philadelphia, PA 19140, USA

Data availability

The data generated during and/or analyzed in the current study are available from the corresponding author on reasonable request. Supplementary Information is available at the Cell Death and Disease’s website.

Conflict of interest

The authors declare that they have no conflict of interest.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

accompanies this paper at https://doi.org/10.1038/s41419-020-2454-8.

Received: 9 September 2019 Revised: 2 April 2020 Accepted: 6 April 2020 Published online: 20 April 2020

References

1. Farquhar, M. J. & Bowen, D. T. Oxidative stress and the myelodysplastic syndrome. Int. J. Hematol. 77, 342–350 (2003).
2. Salminen, A., Fan, J. & Raisio, F. V. Genomic instability in myeloid malignancies: increased reactive oxygen species (ROS), DNA double strand breaks (DSBs) and error-prone repair. Cancer Lett. 270, 1–9 (2008).
3. Miller, B. A. & Zhang, W. TRP channels as mediators of oxidative stress. Adv. Exp. Med. Biol. 704, 531–544 (2011).
4. Hole, P. S., Darley, R. L. & Tonks, A. Do reactive oxygen species play a role in myeloid leukemias? Blood 117, 5816–5836 (2011).
5. Schumacker, P. T. Reactive oxygen species in cancer cells: live by the sword, die by the sword. Cancer Cell 10, 175–176 (2006).
6. Trachootham, D., Alexandre, J. & Huang, P. Targeting cancer cells by ROS-meditated mechanisms: a radical therapeutic approach? Nat. Rev. Drug Discov. 8, 579–591 (2009).
7. Gilliam, L. A. et al. Doxorubicin acts via mitochondrial ROS to stimulate cat- abolism in C2C12 myotubes. Am. J. Physiol. Cell Physiol. 302, C195–202 (2012).
8. Laurent, G. & Jaffeouz, J. P. Signaling pathways activated by daunorubicin. Blood 98, 913–924 (2001).
9. Townsend, D. M., Findlay, V. L. & Tew, K. D. Glutathione S-transferases as regulators of kinase pathways and anticancer drug targets. Methods Enzymol. 401, 287–307 (2005).
10. Zhang, H., Fang, H. & Wang, K. Reactive oxygen species in eradicating acute myeloid leukemic stem cells. Stem Cell Investig. 1, 13 (2014).
11. Nilius, B., Övstqvist, G., Voigt, T. & Trachootham, D. TRPM2 as a mediator of reactive oxygen species and bioenergetics. Cancer Lett. 270, 1–8 (2009).
12. Duncan, L. M. et al. Down-regulation of the novel gene melastatin correlates with potential for melanoma metastasis. Cancer Res. 58, 1515–1520 (1998).
13. Nagamine, K. et al. Molecular cloning of a novel putative Ca2+-channel protein (TRPC7) highly expressed in brain. Genomics 54, 124–131 (1998).
14. Gaiser, A. et al. Activation of T cell calcium influx by the second messenger adp-ribose. J. Biol. Chem. 281, 2489–2496 (2006).
15. Peraud, A. L. et al. Accumulation of free ADP-ribose from mitochondria mediates oxidative stress-induced gating of TRPM2 cation channels. J. Biol. Chem. 280, 6138–6148 (2005).
16. Toth, B. & Casnady, L. Identification of direct and indirect effectors of the transient receptor potential melastatin 2 (TRPM2) cation channel. J. Biol. Chem. 285, 30091–30102 (2010).
17. Hara, Y. et al. LTPRC2 Ca2+-permeable channel activated by changes in redox status confers susceptibility to cell death. Mol. Cell. 9, 163–173 (2002).
18. Du, J., Xie, J. & Yue, L. et al. Intracellular calcium activates TRPM2 and its alternative spliced isoforms. Proc. Natl Acad. Sci. USA 106, 7239–7244 (2009).
19. Tong, Q. et al. Regulation of the transient receptor potential channel TRPM2 by the Ca2+ sensor calmodulin. J. Biol. Chem. 281, 9076–9085 (2006).
20. Orfanelli, U. et al. Identification of novel sense and antisense transcription at the TRPM2 locus in cancer. Cell Res. 18, 1128–1140 (2008).
21. Chen, S. J. et al A splice variant of the human ion channel TRPM2 modulates neuroblastoma tumor growth through hypoxia-inducible factor (HIF)-1 β/Ζa/ζa. J. Biol. Chem. 289, 36284–36302, https://doi.org/10.1074/jbc.M114029222 (2014).
22. Park, Y. R. et al. Data-driven analysis of TRP channels in cancer: linking variation in gene expression to clinical significance. Cancer Genom. Proteom. 13, 83–90 (2016).
23. Sumoza-Toledo, A. & Penner, R. TRPM2: a multifunctional ion channel for cal- cium signalling. J. Physiol. 589, 1515–1525 (2011).
24. Knowles, H. et al. Transient Receptor Potential Melastatin 2 (TRPM2) ion channel is required for innate immunity against Listeria monocytogenes. Proc. Natl Acad. Sci. USA 108, 11578–11583 (2011).
25. Bai, J. Z. & Lipski, J. Differential expression of TRPM2 and TRPV4 channels and their potential role in oxidative stress-induced cell death in organotypic hip- pocampal culture. Neurotox Res. 31, 204–214 (2018).
26. Di, A. et al. The redox-sensitive cation channel TRPM2 modulates phagocyte ROS production and inflammation. Nat. Immunol. 13, 29–35 (2012).
27. Miller, B. A. TRPM2 in cancer. Cell Calcium 50, 8–17 (2019).
28. Miller, B. A. et al. The second member of transient receptor potential-melastatin channel family protects hearts from ischemia-reperfusion injury. Am. J. Physiol. Heart Circ. Physiol. 304, H1010–H1022 (2013).
29. Hoffman, N. E. et al. Ca(2)2+ entry via TRPM2 is essential for cardiac myocyte bioenergetics maintenance. Am. J. Physiol. Heart Circ. Physiol. 308, H637–H650 (2015).
30. Hermosura, M. C. et al. Altered functional properties of a TRPM2 variant in Guamanian ALS and PD. Proc. Natl Acad. Sci. USA 105, 18029–18034 (2008).
31. Bao, L. et al. Depletion of the Human Ion Channel TRPM2 in neuroblastoma demonstrates its key role in cell survival through modulation of mitochondrial reactive oxygen species and bioenergetics. J. Biol. Chem. 291, 24449–24464, https://doi.org/10.1074/jbc.M1167471417 (2016).
